Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
7
|
| gptkbp:bfsParent |
gptkb:5-fluorouracil
|
| gptkbp:activities |
gptkb:fragrance
|
| gptkbp:appointed_by |
healthcare professional
injection |
| gptkbp:approves |
gptkb:1962
gptkb:FDA |
| gptkbp:caused_by |
neurotoxicity
cardiotoxicity hand-foot syndrome myelosuppression |
| gptkbp:contraindication |
pregnancy
breastfeeding |
| gptkbp:developed_by |
gptkb:Eli_Lilly_and_Company
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fluorouracil Injection
|
| gptkbp:ingredients |
C4 H3 F N2 O2
|
| gptkbp:interacts_with |
gptkb:methotrexate
gptkb:warfarin |
| gptkbp:is_available_in |
syringes
vials |
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_monitored_by |
kidney function
liver function blood cell counts |
| gptkbp:is_part_of |
FOLFIRI regimen
CAPOX regimen FOLFIRINOX regimen FOLFOX regimen combination chemotherapy regimens |
| gptkbp:is_tested_for |
temperature fluctuations
light sensitivity p H changes |
| gptkbp:is_used_for |
treating cancer
|
| gptkbp:is_used_in |
palliative care
live vaccines adjuvant therapy neoadjuvant therapy other cytotoxic agents |
| gptkbp:manager |
intravenous
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
fatigue
nausea vomiting diarrhea mouth sores |
| gptkbp:storage |
room temperature
|
| gptkbp:suitable_for |
gptkb:Person
patients with severe renal impairment elderly patients with comorbidities patients with severe hepatic impairment |
| gptkbp:targets |
thymidylate synthase
|
| gptkbp:used_in |
gptkb:healthcare_organization
stomach cancer head and neck cancer |
| gptkbp:weight |
130.09 g/mol
|